Lantheus Holdings LNTH Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cardiology | $84.63M— | —— | —— | —— | $79.21M— | |
| Definity | $84.63M-0.8% | $85.31M+4.3% | $81.79M-2.6% | $83.94M+6.0% | $79.21M-8.1% | |
| Licenseand Royalty Revenues | $7.48M-56.9% | $17.37M+137% | $7.33M+109% | $3.5M-40.2% | $5.85M+95.0% | |
| Neuraceq | $35.44M+14.3% | $31.01M+51.7% | $20.44M— | $0— | $0— | |
| Neurology | $35.44M— | —— | —— | —— | $0— | |
| Oncology | $240.92M— | —— | —— | —— | $257.65M— | |
| PYLARIFY | $240.92M+0.3% | $240.2M-0.2% | $240.62M-4.0% | $250.64M-2.7% | $257.65M-3.1% | |
| SPECT Business | $0— | —— | —— | —— | $25.15M— | |
| Strategic Partnerships And Other | $16.34M-30.0% | $23.34M+70.3% | $13.71M+18.2% | $11.59M+7.8% | $10.75M+39.7% | |
| Revenue by Geography | ||||||
| Non Us | $22.91M— | —— | —— | —— | $15.01M+22.0% | |
| US | $354.43M— | —— | —— | —— | $357.76M-3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Lantheus Holdings break its business down?
- Lantheus Holdings (LNTH) reports revenue by product across 9 parts — Cardiology, Definity, Licenseand Royalty Revenues, Neuraceq and Neurology. Each is extracted from the segment footnotes and tracked over time.
- Where does Lantheus Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Lantheus Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
